Video

Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

Author(s):

Neal Shore, MD, FACS

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.

Related Videos
Oliver Sartor, MD, is featured in this series.
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Michael Jenson, PA-C, answers a question during a Zoom video interview
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
FDA accepts sNDA for darolutamide plus ADT in mHSPC
November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke
The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC
November 13th 2024

ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC

Hannah Clarke
Final completion of the ECLIPSE trial is anticipated for February 2029.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Phase 1/2 trial of ONCT-534 in mCRPC has been terminated
November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke
The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.
Trial launches of Barrigel rectal spacer for post-prostatectomy radiation therapy
November 5th 2024

Trial launches of Barrigel rectal spacer for post-prostatectomy radiation therapy

Hannah Clarke
In total, the study plans to enroll 84 adult patients across clinical trial sites in the United States and Australia.
© 2024 MJH Life Sciences

All rights reserved.